OJSC Pharmstandard (PHST) - Acquisition RNS Number : 7052R OJSC Pharmstandard 21 November 2012 Pharmstandard OJSC announces the Acquisition of a 100% stake in "LEKKO" CJSC. Moscow, November 21, 2012 -O JSC Pharmstandard announces the acquisition of 100% stake in "LEKKO" CJSC. On September 6, 2012 Russia's Federal Antimonopoly Service (FAS) has granted approval for OJSC Pharmstandard's bid to acquire 100% of the voting shares of CJSC "LEKKO". "LEKKO" CJSC is a Russian innovative company which performs in the field of research and development of highly effective drugs as well as their production and distribution. The company has an 18-year track record of successful market presence and it's products are a result of years of successful investments into promising scientific researches in the field of traditional medicine. "LEKKO" CJSC production facilities are located in Volginsky village (Vladimir region). Annual output amounts to 50 million packs of 11 pharmaceutical products. The company employs 400 highly-qualified professionals in the field of medicine and pharmacy, biology and chemistry, management, marketing and technology. "LEKKO" CJSC 2011 audited revenues amounted to RUR684.4m. 3Q2012 revenues reached RUR357.6m. Pharmstandard OJSC uses LEKKO facilities to produce Rinostop® and Acipol®. 3Q2012 sales of these drugs amounted to RUR111.6m and RUR266.04m accordingly. Pharmstandard OJSC management believes that the acquisition of LEKKO is highly effective for further successful production of Rinostop® and Acipol® as well as for the expansion of business in general. Irina Bakhturina Investor Relations OJSC Pharmstandard +7 495 970 00 30 ext.2824 www.pharmstd.com About the Pharmstandard group of companies The main sphere of activity of the enterprises comprising the Pharmstandard group of companies, are developing and manufacturing of high-quality modern pharmaceutical products which meet the requirements of the healthcare system and the expectations of patients. The most well-known Pharmstandard products today are Arbidol®, Complivit®, Pentalgin®, Flucostat®, Phosphoglive®, Amixin®, Afobazol®, Rastan® and Biosulin®. The Pharmstandard group of companies manufactures more than 250 pharmaceutical products, including medicines for the treatment of cardio-vascular diseases, diabetes, growth hormone deficiency, gastroenterological, neurological, contagious diseases, metabolic disorders, cancer and other diseases. More than 100 Pharmstandard products (taking into account all forms and dosages) are included in the list of Vital and Essential Pharmaceuticals. In the period from 2004 to 2011 more than 60 new pharmaceutical products were developed by Pharmstandard, in co-operation with the leading Russian scientific centres. Pharmstandard is a participant in a joint bio-engineering project, Generium, whose objective is the development of socially significant pharmaceutical products within the framework of the state program of import substitution. By 2011 the Сompany's aggregate production capacity has reached more than 1,46 billion packages per year. The production capacity of the Pharmstandard group of companies comprises four modern pharmaceutical plants: JSC Pharmstandard-Leksredstva (Kursk), JSC Pharmstandard-UfaVita (Ufa), JSC Pharmstandard-Tomskhimpharm (Tomsk), JSC Pharmstandard-Biolek (Kharkov, Ukraine) and the medical equipment and tools plant JSC TZMOI (Tyumen); Pharmstandard LLC is responsible for the purchase and supply of raw materials for manufacturing of pharmaceutical products at the production facilities of the Pharmstandard group of companies. All the production facilities of the Pharmstandard group of companies fully comply with Russian national standards, while six production lines at JSC Pharmstandard-Leksredstva have already received certificates of compliance with the EU GMP standards. All the plants are expected to convert to European GMP standards by 2014, according to the schedule approved by the company's management. On 4 May 2007 Pharmstandard placed its shares during IPO on Russian Trading System (RTS), Moscow Interbank Currency Exchange (MICEX) and Global Depositary Receipts (GDR) at London Stock Exchange (LSE). www.pharmstd.com This information is provided by RNS The company news service from the London Stock Exchange END ACQEADFFAFPAFFF -0- Nov/21/2012 14:00 GMT
OJSC Pharmstandard PHST Acquisition
Press spacebar to pause and continue. Press esc to stop.